
    
      This is an open-label study of CEP-701 in patients with refractory, relapsed, or poor risk
      AML expressing FLT-3 activating mutations. Patients who meet eligibility criteria will be
      enrolled at a dosage of 60 mg orally 2 times a day for 28 days (1 cycle). Upon completion of
      cycle 1, the dosage may be increased to 80mg 2 times a day or decreased to 40 mg 2 times a
      day, dependent upon response to 60 mg dosage.
    
  